--- a
+++ b/clusters/3009knumclusters/clust_278.txt
@@ -0,0 +1,398 @@
+Patients must not have received previous irradiation for head and neck tumor, skull base, or brain tumors
+Patient must not have had previous irradiation to the head and neck that would result in overlap in radiation fields for the current disease
+INELIGIBLE SITES: Head and neck, visceral organs (with the exception of embryonal sarcoma of the liver), retroperitoneum, peritoneum, pelvis within the confines of the bony pelvis
+Prior chemotherapy or radiosensitizers for cancers of the head and neck region; note that prior chemotherapy for a different cancer is allowable (except temozolomide)
+Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields
+Head and neck carcinoma (H&N). Salivary glands tumors are excluded.
+Subject has a metal implant, including a programmable shunt, in the head or neck that is incompatible with MRI.
+No prior radiation therapy to the head and neck; prior radiation therapy to body sites other than the head and neck are permitted provided that the treating radiation oncologist determines that there is no overlap between the head and neck radiation plan and the prior radiation fields
+Participants who have had prior radiation therapy to the head and neck
+No active malignancy; participants that received curative treatment for a prior cancer are eligible provided there is no prior head and neck radiation and no prior chemotherapy or anti-EGF or anti-HER2 therapy as above
+Patients with prior radiation to the head and neck
+Prior history of radiation therapy to the head and neck
+Prior history of head and neck cancer
+Squamous Cell Carcinoma of the Head and neck (SCCHN)
+Non-viral-associated head and neck squamous cell carcinoma (HNSCC) or HPV-associated HNSCC after failure of prior therapy
+For Part C exclusively (RO6874281 in combination with cetuximab), participants with metastatic or recurrent or locally advanced squamous cell carcinoma of head and neck who have progressed on cetuximab maintenance therapy after cetuximab-containing chemotherapy or radiation therapy
+Must have diagnosis of head and neck squamous cell carcinoma of the oropharynx (tonsil, base of tongue, soft palate, or oropharyngeal walls), hypopharynx, or larynx
+Must not have received any of the following prior therapies or treatments: systemic therapy for the study cancer, radiation therapy to the head and neck region, or curative-intent surgery in the head and neck region
+Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
+Squamous cell carcinoma of the head and neck;
+Subject must have histologically or cytologically confirmed locoregionally recurrent squamous cell carcinoma of the head and neck (including any primary site, such as oral cavity, oropharynx, larynx or hypopharynx, and nasopharynx carcinoma)
+Pathologically confirmed head and neck squamous cell carcinoma (HNSCC)
+Prior radiation to the head and neck
+Histologically or cytologically confirmed diagnosis of stage III/IV recurrent and/or metastatic squamous cell carcinoma of the head and neck not suited for local therapy
+Malignancies other than head and neck cancer within 5 years prior to Day 1 of treatment, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
+Has a history of re-irradiation for squamous cell carcinoma of the head & neck (SCCHN) at the projected injection site.
+Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis or thoracic cavity within the last three years are excluded; prior radiation for localized cancer of the head and neck or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
+Prior radiation to the head and neck region
+Prior radiotherapy to the head or neck (except for T1 glottic cancer), that would result in overlap of radiation fields.
+Prior radiation therapy to the larynx area or involved neck.
+Patients must have an immune checkpoint resistant malignancy (for example, RCC, head and neck carcinoma or MSI high cancers which have approved settings for anti-PD1 treatment), confirmed histologically or cytologically.
+Must be willing to undergo definitive resection with neck dissection.
+Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields
+Diagnosis of selected stage III or IVa/b head and neck squamous cell carcinoma (HNSCC); all patients must have T2-T4 primary tumors (patients with T1 tumors will be excluded); although most of these patients will have regional nodal disease, patients with no nodal disease will also be eligible
+Diagnosis of unknown primary squamous cell carcinoma of the head and neck
+Participants must have a pathologic cancer diagnosis:\r\n* COHORT I: Squamous cell carcinoma of the head and neck, nasopharyngeal cancer, or salivary gland cancer\r\n* COHORT II: Solid tumor to the head and neck amenable to palliative treatment, including but not limited to squamous cell carcinoma, adenocarcinoma, sarcoma, melanoma, NK/T lymphoma, poorly differentiated thyroid cancer, and anaplastic thyroid cancer
+COHORT I: History of radiation to the head and neck area (defined as above the clavicles) greater than 6 months previous
+COHORT I: Pathologically proven recurrent disease or a second primary (squamous cell carcinoma of the head and neck, nasopharyngeal cancer, or salivary gland cancer) within the head and neck region, deemed to be unresectable or resected with gross residual disease remaining or microscopically positive margins defined as closer than 5mm (determined by either operative/pathology report or postsurgical imaging)
+COHORT II: Pathologically proven solid tumor in the head and neck that are amenable to palliative treatment
+Squamous head and neck cancer
+In the opinion of the local PI: Head and neck cancer patients with airway tumor recurrence that may compromise breathing or swallowing if inflammation or edema is transiently aggravated by Hiltonol injection. Head and neck cancer patients with tumor invading major blood vessels for whom there may be a risk of blockage or bleeding if inflammation or edema is transiently increased by Hiltonol injections.
+Prior treatment for head and neck cancer
+A history of other malignancy =< 3 years previous with the exception of previous head and neck cancer treated only by surgery, basal cell or squamous cell carcinoma of the skin which were treated with local resection only, or carcinoma in situ of the cervix\r\n* Note: patients with synchronous head and neck cancer primaries are an exception to this criterion and may qualify for the study
+No previous surgery, radiation therapy or chemotherapy for head and neck squamous cell carcinoma (SCCHN) (other than biopsy or tonsillectomy) is allowed at time of study entry
+Histologically-proven recurrent squamous cell carcinoma of the head and neck (SCCHN), who has received prior radiotherapy with or without chemotherapy; new primary is allowed if location is in a previously irradiated field; biopsy is recommended for each recurrence but is not mandated per study; this will be at the discretion of the principal investigator
+Prior head and neck radiation
+COHORT B, GROUP 4: HEAD AND NECK SQUAMOUS CELL CANCER: Patients with head and neck squamous cell carcinoma must have failed a platinum based chemotherapy regimen that was administered for advanced disease with a palliative intent: patients treated with concurrent platinum agent and radiation as definitive therapy are not eligible unless they subsequently received another line of systemic therapy
+Tumour located above the clavicle and below the jaw or occiput (neck primary) or above the jaw/occiput (head primary)
+Previous radical radiation therapy to the head and neck, excluding superficial radiation therapy to cutaneous SCC or basal cell carcinoma, which is not within or overlapping the tumour bed
+Histologically confirmed squamous cell carcinoma of the head and neck, including the following subtypes: oral cavity, oropharynx, hypopharynx, larynx.
+Histologically proven recurrent/metastatic squamous cell carcinoma arising from a previous head and neck primary site, and located within the head and neck region, lung or bone, and who are not candidates for curative intent therapy
+Patients must have histologically confirmed squamous cell carcinoma of the head and neck (unresectable and not amenable to curative intent therapy)
+Histologically confirmed metastatic or recurrent squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx & larynx) that is not amenable to curative therapy.
+Prior chemo therapy or radiosensitizer for head and neck cancer
+Prior radiotherapy to the head or neck in overlap of radiation fields
+Prior head and neck radiation, chemotherapy, or immunotherapy
+Patients must be evaluated by a head and neck surgeon and be deemed surgically resectable at baseline
+Any prior radiotherapy to the neck
+A previous diagnosis of histologically defined head and neck cancer.
+A diagnosis of head and neck lymphedema.
+The head and neck garments must fit appropriately. For patients with a tracheostomy, the fit will be assessed to ensure that the garments do not interfere with their tracheostomy.
+Facial or head and neck dermal metastasis.
+Histologically proven advanced or metastatic non-small cell lung cancer or squamous cell carcinoma head and neck with tumor at least 1 cm in size
+Prior radiation therapy to head and neck region that would overlap with intended radiation treatment for nasopharyngeal carcinoma
+Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis or thoracic cavity within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
+No head and neck surgery of the primary tumor or lymph nodes except for incisional or excisional biopsies.
+Previous radiation treatment for head and neck mucosal primary cancers within the past 5 years (i.e. oropharynx, nasopharynx, hypopharynx, larynx, and oral cavity).
+Carcinoma of the neck of unknown primary site origin (even if p16 positive)
+Histologically documented progressive squamous cell head and neck cancer with or without metastases, not amenable to curative treatment; or the patient has documented refusal of curative treatment
+Previously untreated, histologically proven, surgically resectable primary squamous cell carcinoma of the head and neck, stage III or IV (human papilloma virus [HPV] positive or negative non-metastatic disease); SCCHN of unknown primary is excluded; SCCHN of the oral cavity is allowed; unambiguously squamous Epstein-Barr virus (EBV)-negative nasopharynx cancer will not be excluded nor will unambiguously squamous cancers of the skull base that are clearly surgically resectable and clearly squamous; squamous skin cancer occurring in the head/neck region will not be eligible nor will EBV+ nasopharynx cancer\r\n*Note: Induction chemotherapy is not considered standard therapy for SCCHN of the oral cavity and participation on this trial will lead to a delay in time to definitive, potentially curative therapy i.e, surgery
+Patients with histologically documented recurrent head and neck cancer, or second primary head and neck cancer, AND who have previously received radiation (at least 30 Gy) for head and neck cancer
+Primary tumors of any head and neck (oral cavity, oropharynx, hypopharynx, or larynx) site will be included
+Surgical resection of head and neck must be planned, either as primary treatment or salvage; patients must undergo research biopsy prior to receiving drug
+Prior therapy for head and neck cancer is allowed, and the number of treatments is not limited; however, any systemic therapy should have been completed at least 30 days prior to study enrollment; any radiation to the head and neck should have been completed at least 30 days prior to study enrollment; palliative radiation outside of the\r\nhead and neck does not require a washout
+Prior radiation therapy to the head and neck region.
+Patients must have pathologically confirmed HPV-positive head and neck squamous cell carcinoma of the oropharynx; confirmed HPV-positive disease of other subsites are uncommon but also eligible
+No previous radiation or chemotherapy for a head and neck cancer
+Histologically or cytologically proven squamous cell carcinoma of the head and neck (lip, oral cavity, oropharynx, larynx, hypopharynx, non- Epstein–Barr virus [EBV] related nasopharynx, sinonasal, cutaneous), not amenable to curative intent therapy
+Diagnosis of head and neck squamous cell carcinoma that is either biopsy proven or suspected based on history, physical, and or radiographic findings, and who are planned for definitive resection of the tumor without the use of neoadjuvant chemotherapy or radiation therapy at Thomas Jefferson University Hospital (TJUH) are eligible to participate
+Received prior cancer therapy for the head and neck squamous cell carcinoma (HNSCC) that is being resected
+Histologic diagnosis of cutaneous squamous cell carcinoma of the head and neck that has been resected with no evidence of gross residual disease (margin positivity is acceptable)
+Histologically confirmed recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) (oral cavity, oropharynx, hypopharynx, or larynx) not amenable to therapy with curative intent (surgery or radiation therapy with or without chemotherapy); patients who refuse radical resection are eligible
+Histologically confirmed squamous cell carcinoma of any other primary anatomic location in the head and neck (e.g. paranasal cavity) and non-squamous histologies (e.g. nasopharynx or salivary gland)
+Patients must have pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity, oropharynx, larynx, hypopharynx, paranasal sinuses or unknown primary squamous carcinoma limited to the head and neck region\r\n* Cohort 1: unresectable locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN) without evidence of distant metastases\r\n* Cohort 2: patients with non-nasopharyngeal SCCHN who have undergone gross total surgical resection within 63 days prior to registration; patients must have at least 1 of the following high-risk pathologic features: extracapsular nodal extension, invasive cancer at the primary tumor resection margin (positive margin), lymphovascular invasion or perineural invasion, or the presence of multilevel nodal disease; patients must be without evidence of distant metastases
+Patients may have a history of prior head and neck malignancy, but must be able to tolerate full dose radiation and chemotherapy for the current head and neck cancer, as determined by the treating oncologist
+No prior chemotherapy for the current locally advanced SCCHN is allowed; prior radiation or chemotherapy for a previous head and neck cancer is allowed provided full dose cisplatin and radiation can be delivered to the patient in this clinical trial and provided the patient is in remission from the prior head and neck cancer, and can undergo full dose radiation and chemotherapy for the current primary head and neck cancer
+Patients with distant metastatic disease (M1c) from the current head and neck cancer including brain metastasis
+Limited neck dissections retrieving ? 4 nodes are permitted and considered as non-therapeutic nodal excisions. Fine needle aspirations of the neck that are positive for squamous cell carcinoma are sufficient for diagnosis pending pathology review at participating institutions.
+Pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma
+Examination by an ear/nose/throat (ENT) or head and neck surgeon, including laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure) within 8 weeks prior to enrollment.
+Histologically or cytologically confirmed squamous cell carcinoma of the head and neck that is metastatic or recurrent and not treatable with curative intent
+No previous surgery, radiation therapy or chemotherapy for squamous cell carcinoma of the head and neck (SSCHN) (other than biopsy or tonsillectomy) is allowed at time of study entry
+History of any other cancer other than head and neck cancer (HNC) (except carcinoma in situ of the cervix) within the last 5 years.
+Patients treated with previous cranial or head/neck radiotherapy leading to radiation field overlap
+Subjects must have histologically or cytologically confirmed recurrent head and neck cancer
+Patients with recurrent/previous treated head and neck squamous cell carcinoma that is deemed surgically resectable by the treating physician but at high risk for recurrence; this group otherwise would be considered for retreatment with radiation and/or chemoradiation
+Patients must have pretreatment neck and chest imaging
+Prior head and neck radiation or prior chemotherapy for head and neck squamous cell carcinoma (HNSCC)
+Histologically documented squamous cell head and neck cancer with or without metastases, not amenable to curative treatment; or the patient has documented refusal of curative treatment
+Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
+Histologic diagnosis of solid malignant tumor including but not limited to non-small cell lung cancer, breast, prostate, renal cell, melanoma, gastrointestinal, sarcoma, thyroid, head and neck primary, and unknown primary tumors
+Histologically documented diagnosis of squamous cell carcinoma of the head/neck including nasopharyngeal carcinomas (lymphepithelioma histology is ok if criteria 2 is met)\r\n* Patients must have progressed on prior platinum based therapy (or have become intolerant) prior to enrollment on this study
+Have histologically or cytologically-confirmed head and neck squamous cell carcinoma of the oral cavity (excluding lip), oropharynx, hypopharynx, or larynx.
+Prior treatment with radiation to the head and neck
+Pathologically proven recurrent or second-primary head-and-neck cancer receiving prior radiotherapy with or without chemotherapy
+Radiation therapy to head and neck (excluding eyes), and internal organs of chest, abdomen or pelvis in the month prior to enrollment
+Having received radiation therapy to head and neck (excluding eyes), and internal organs of chest, abdomen or pelvis in the month prior to enrollment
+ARM B COHORT 2: Patients must have a histologically confirmed diagnosis of head and neck (squamous cell) carcinoma
+ARM B COHORT 2: Patients with head and neck cancer must not have radiologic evidence of major arterial involvement
+Subjects with a diagnosis of recurrent head and neck cancer
+Prior radiation therapy to the head or neck resulting in overlap of radiotherapy (RT) fields
+Determined by the treating physician to be a candidate for organ preserving, concurrent standard chemotherapy and radiation therapy to the head and neck with definitive intent
+Prior radiation therapy to the head and neck
+Neck adenopathy that involves the overlying skin
+Initial surgical treatment including tonsillectomy or neck dissection, but excluding diagnostic biopsy of the primary site or nodal sampling of neck disease
+Prior radiation therapy to the head and neck
+Presence of N0 or N1 disease in neck dissection
+Recurrence of previously pathologically proven squamous cell carcinoma of the head and neck, including original primary sites in the paranasal sinuses, nasal cavity, nasopharynx, oropharynx, oral cavity, larynx, hypopharynx, salivary glands, and/or involvement of cervical lymph nodes
+Patients with stage III/IV per tumor/nodes/metastasis (TNM) guidelines for head and neck sites (American Joint Committee on Cancer [AJCC] 7th Edition), locally advanced, biopsy proven squamous cell cancer of the head and neck that undergo chemoradiation as their primary treatment with curative intent; patients with oropharynx (human papillomavirus [HPV] positive and HPV negative), hypopharynx, larynx primaries, nasopharynx as well as those with documented squamous cell cancer (SCC) of the cervical lymph nodes, with unknown primaries, are eligible
+Patients who have received prior radiation to the head and neck or adjacent anatomical site (e.g., upper lobe lung, brain)
+The patient has had prior head and neck squamous cell carcinoma (HNSCC), with the exception of superficial cutaneous basal cell or squamous cell carcinomas
+Histological or cytological documentation of recurrent head and neck cancer requiring regional therapy
+Recurrent or second primary, previously irradiated squamous cell carcinoma of the head and neck (SCCHN) without clinically measurably metastatic disease
+Primaries on the torso, upper and lower extremities and head and neck region
+Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in significant overlap of radiation fields
+Radiation therapy to head and neck (excluding eyes), and internal organs of chest, abdomen or pelvis in the month prior to enrollment
+Prior head and neck radiation or prior chemotherapy
+Patients with prior radiation to the head and neck
+Previous irradiation for head and neck tumor, skull base, or brain tumors
+Previous head and neck surgery that would preclude transoral/robotic procedures; this is at the investigator’s discretion; this is not an exclusion criterion for the non-surgical arm
+Additional inclusion for Part B:Has histologically and/or cytologically confirmed SCCHN that is RM and not amendable to curative therapy by surgery or radiation. Squamous cell carcinoma of the head and neck originating from the following sites is eligible: oral cavity, oropharynx, larynx, or hypopharynx. Has at least 1 SCCHN tumour lesion (TL) amenable to biopsy and must have failed, refused, or has been found to be ineligible for least 1 prior platinum-based chemotherapy for RM-SCCHN Additional inclusion criteria for Arms B1 & B2:must have had prior exposure to anti PDL-1 antibody
+histologically or cytologically confirmed diagnosis of thyroid cancer (cohort 1) or squamous head and neck cancer (cohort 2) for which there is no curative therapy available.
+Malignant solid tumor (e.g. squamous cell carcinoma of the head/neck/cervix) within 2 years if HCT
+Head and neck oropharyngeal, hypopharyngeal, or oral cavity lesions requiring surgical resection, biopsy, or invasive treatment
+History of squamous cell carcinoma of the head/neck/cervix within 2 years of HSCT
+Histological or cytological documentation of squamous cell carcinoma of the head and neck (SCCHN) (oral cavity, oropharynx, hypopharynx, or larynx) that is recurrent, locally advanced, or metastatic and is not amenable to curative treatment options, surgery or definitive chemoradiation therapy.
+Prior radiation to the head and neck
+Prior radiation therapy to the head and neck
+No previous surgery, radiation therapy or chemotherapy for squamous cell carcinoma of the head and neck (SSCHN) (other than biopsy or tonsillectomy) is allowed at time of study entry
+Head and neck cancer - squamous cell
+Arm C patients must have loco-regional recurrent head and neck squamous cell carcinoma (HNSCC), excluding endolaryngeal recurrence, meeting the following criteria:
+All HNSCC lesions should be in the head and neck region and suitable for intra-tumoral injection
+ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Tumor involvement of the following sites or any of these signs or symptoms likely to be associated with T4b cancer:\r\n* Involvement of pterygopalatine fossa, maxillary sinus, or facial skin\r\n* Gross extension of tumor to the skull base\r\n* Pterygoid plate erosion\r\n* Sphenoid bone or foramen ovale involvement\r\n* Direct extension to involve prevertebral fascia\r\n* Extension to superior nasopharynx or Eustachian tube\r\n* Direct extension into the neck with involvement of the deep neck musculature (neck node fixation)\r\n* Suspected invasion (encasement) of the common or internal carotid arteries; encasement will be assessed radiographically and will be defined as tumor surrounding the carotid artery 270 degrees or greater\r\n* Direct extension of neck disease to involve the external skin\r\n* Direct extension to mediastinal structures\r\n* Regional metastases to the supraclavicular neck (low level VB and IVB)
+HPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Tumor involvement of the following sites or any of these signs or symptoms likely to be associated with T4b cancer:\r\n* Involvement of pterygopalatine fossa, maxillary sinus\r\n* Gross extension of tumor to the skull base\r\n* Pterygoid plate erosion\r\n* Sphenoid bone or foramen ovale involvement\r\n* Direct extension to involve prevertebral fascia\r\n* Extension to superior nasopharynx or Eustachian tube\r\n* Direct extension into the neck with involvement of the deep neck musculature (neck node fixation)\r\n* Suspected invasion (encasement) of the common or internal carotid arteries; encasement will be assessed radiographically and will be defined as tumor surrounding the carotid artery 270 degrees or greater\r\n* Direct extension of neck disease to involve the external skin\r\n* Direct extension to mediastinal structures\r\n* Regional metastases to the supraclavicular neck (low level VB and IVB)
+Biopsy-proven, primary or recurrent advanced-stage (III/IV) cutaneous squamous cell carcinoma of the head and neck.
+Patients treated with previous cranial or head/neck radiotherapy leading to significant radiation field overlap.
+Prior treatment with cabozantinib or pembrolizumab; or any prior immunotherapy for treating squamous cell carcinoma of the head and neck
+Histologically confirmed squamous cell carcinoma of the head and neck including the oral cavity, oropharynx, hypopharynx or larynx, excluding nasopharynx
+No prior systemic chemotherapy, systemic biologic/molecular targeted therapy or radiation treatment for head and neck cancer
+History of radiation to the head and neck (above the clavicles)
+Recurrent and/or metastatic Kras wildtype colorectal cancer or squamous cell carcinoma of the head and neck
+Previous therapy:\r\n* Patients must have progressed after standard therapy for metastatic/recurrent disease; this must have included irinotecan and oxaliplatin-containing regimens for patients with colorectal cancer (CRC) and platinum-containing regimens for patients with head and neck squamous cell carcinoma (H&NSCC)\r\n* Patients may have received cetuximab or panitumumab previously
+Examination by Radiation Oncologist, Medical Oncologist, and Ear, Nose, Throat (ENT) or Head & Neck Surgeon within 28 days prior to registration
+Patients with oral cavity cancer are excluded from participation if resection of the primary tumor is considered technically feasible by an oral or head and neck cancers surgical subspecialist.
+Carcinoma of the neck of unknown primary site origin (even if p16-positive).
+Patients must have stage III-IVB head and neck squamous cell carcinoma (HNSCC) (American Joint Committee on Cancer [AJCC] seventh [7th] edition) based on the following minimum diagnostic workup within 60 days prior to step 1 registration: \r\n* General history and physical examination by a radiation oncologist, medical oncologist, and/or ear, nose and throat (ENT) or head & neck surgeon\r\n* For larynx, hypopharynx, and base of tongue primaries, a laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure) is required, unless the patient cannot tolerate or refuses\r\n* Imaging of the head and neck with a neck CT or magnetic resonance imaging (MRI) (with contrast, unless contraindicated) or PET/CT (with contrast, unless contraindicated)\r\n* Chest imaging: chest CT with and without contrast (unless contraindicated) or PET/CT
+Patients with localized sarcomas that are not of the extremity or trunk wall (including head/neck, retroperitoneum, visceral organs, peritoneum, pelvis within the confines of the bony pelvis, and tumors arising in bone)
+Pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity (excluding lips), oropharynx (p16 negative), hypopharynx or larynx
+Pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity (excluding lips), oropharynx (p16 negative), larynx, or hypopharynx
+Pathologically confirmed squamous cell carcinoma of the head and neck (SCCHN), not previously treated
+Any prior radiotherapy to the neck
+Patients may not have received previous therapy for their head and neck SCC, including chemotherapy, radiation therapy, or surgery beyond biopsy
+Prior neck radiotherapy that would preclude re-irradiation
+Previous head and neck radiation therapy
+Prior chemotherapy or radiotherapy for the diagnosis of GBM or for cancers of the head and neck
+Carcinoma of the neck of unknown primary site origin (even if p16 positive)
+Biopsy proven squamous cell carcinoma of the head and neck (SCCHN)
+Prior history of radiation to the head and neck region
+Any head and neck cancer of non-squamous histology
+Any head and neck subsite other than oropharynx (including unknown primary site)
+Patients receiving any prior radiation therapy to the head or neck
+Prior head and neck malignancy or history of other prior non-head and neck malignancy (excluding skin cancer and early stage treated prostate cancer) within the past 3 years
+Prior head and neck radiation or chemotherapy
+Patients with concurrent primary head and neck tumors that will be resected as part of treatment plan are considered eligible
+Patients with head and neck cancer recurrence requiring surgery with no history of prior chemotherapy or radiation therapy are considered eligible
+Patients must not have had any prior chemotherapy or radiation therapy for head and neck cancer treatment
+Patients must have histologically-proven recurrent and/or metastatic squamous cell carcinoma of the head and neck that is unresectable; patients in the phase II portion of the trial must have measurable disease
+Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
+Patients must have pathologically-confirmed, previously untreated, clinically accessible (without general anesthesia) locally advanced squamous cell carcinoma of the larynx, hypopharynx, oropharynx, or oral cavity or nonresectable head and neck squamous cell carcinomas of the skin
+Prior head and neck malignancy, or history of other prior non-head and neck malignancy within the past 3 years (excluding skin cancer and early stage treated prostate cancer)
+Prior head and neck radiation or chemotherapy
+Pathologically (histologically or cytologically) confirmed diagnosis of recurrent or second primary squamous cell carcinoma (SCC) of the oral cavity, oropharynx, hypopharynx, larynx, or recurrent neck metastases with unknown primary; exception from pathology confirmation of tumor recurrence is accepted for patients who originally had pathologically confirmed SCC of the Head and Neck, the new tumor is located in the head and neck area and it is clinically considered as a recurrence of the original tumor, and a tumor biopsy is technically difficult and would expose the patient to unjustified risk; the treating physicians should agree and document the clinical definition of tumor recurrence and should document the increased risk for biopsy
+Prior history of head and neck radiation for head and neck squamous cell carcinoma to no more than 72 Gy and most (> 75%) of the recurrent or second primary tumor volume should be in areas previously irradiated to > 45 Gy
+Confirmed squamous cell head and neck cancer
+Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis within the last three years are excluded; prior vaginal brachytherapy is allowed; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than two years prior to registration, and the patient remains free of recurrent or metastatic disease
+Patients must have histologically or cytologically confirmed head and neck squamous cell cancer (HNSCC) including paranasal sinus cancers but excluding nasopharyngeal carcinomas
+Histologically or cytologically confirmed diagnosis of squamous cell carcinoma of the head and neck
+Previous radiation treatment for head and neck mucosal primary cancers within the past 5 years (i.e. oropharynx, nasopharynx, hypopharynx, larynx, and oral cavity)
+Unilateral neck radiation
+Pathologically confirmed diagnosis of a recurrent or a new primary head and neck cancer
+A history of prior radiation to the head and neck (>= 40 Gy, in 2 Gy/fraction equivalent)
+Histologically or cytologically confirmed head and neck cancer of any other primary anatomic location in the head and neck not specified in the inclusion criteria including patients with SCCHN of unknown primary or non-squamous histologies (eg, nasopharynx or salivary gland)
+Examination by an ENT or Head & Neck Surgeon including laryngopharyngoscopy prior to entering the study.
+Squamous cell carcinoma of head and neck sites, including all pharynx, larynx, oral cavity, skin and para-nasal sinus sites; patients with a diagnosis of nasopharyngeal carcinoma, or squamous cell carcinoma (SCC) of unknown primary presenting in the neck clinically compatible with head and neck mucosal primary sites, are eligible
+direct extension into the neck with involvement of the deep neck musculature (neck node fixation);
+Phase I run in: biopsy proven RMHNSCC with the following primary sites: nasopharynx, paranasal sinus, nasal cavity, skin/cutaneous sites; patients with unknown head and neck primary sites will be enrolled; patients with recurrent or metastatic squamous cell carcinomas of the head and neck (regardless of primary site) who are either unwilling to receive or have contraindications (deemed by treating physician) to standard systemic chemotherapy will also be eligible; patients with biopsy proven RMSGC be eligible as well
+Urethral stricture/bladder neck contracture
+Any prior head or neck irradiation
+Physician recommendation of bilateral neck radiation
+Previous treatment with an EGFR monoclonal antibody (except for past treatment for squamous cell carcinoma of head and neck or metastatic colorectal cancer).
+Non-squamous cell carcinomas of the head and neck region i.e. nasopharyngeal carcinoma (World Health Organization [WHO] type II and III) and salivary gland carcinomas
+Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease.
+Prior radiation therapy to the head and neck region
+Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
+Must have a primary melanoma that is cutaneous (including head, neck, trunk, extremity, scalp, palm, sole).
+Histologically- or cytologically-confirmed recurrent or metastatic head and neck squamous cell carcinoma considered incurable by local therapies
+Histologically confirmed squamous cell carcinoma of any other primary anatomic location in the head and neck;
+Locally and/or regionally advanced (M0) head and neck squamous cell carcinoma (American Joint Committee on Cancer [AJCC] stage III-IVB), cytologically or pathologically confirmed by Department of Pathology at Memorial Sloan-Kettering Cancer Center (MSKCC), for which curative-intent radiation therapy is planned
+Any prior known radiation therapy in head and neck area
+Prior radiation to the head or neck with overlapping radiation fields
+No previous radiation or chemotherapy for a head and neck cancer
+Has histologically- or cytologically-confirmed recurrent disease not amenable to curative treatment with local or systemic therapy, or metastatic (disseminated) head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx that is considered incurable by local therapies
+Histologically confirmed squamous cell carcinoma of any other primary anatomic location in the head and neck
+Patients must have histologically or cytologically confirmed locally advanced head and neck cancer of squamous type stage III, IVA and IV B (larynx, oral cavity, oropharynx and hypopharynx or unknown primary isolated to the head and neck region) and select stage II tumors of the base of the tongue (BOT) (size more than 3 cm), who are appropriate for potentially curative therapy with chemoradiotherapy or surgical resection, as determined by the multidisciplinary head and neck cancer clinical care and research team
+No prior chemotherapy for the current locally advanced squamous cell carcinoma of the head and neck (SCCHN); prior radiation or chemotherapy for a previous head and neck cancer is allowed provided full dose radiation can be delivered to the current treatment and provided the patient remains in remission for greater than 3 years from prior diagnosis
+Prior chemotherapy for the current SCCHN will not be allowed; patients with second primary cancers of the head and neck who remain in remission for 3 years from the prior diagnosis are eligible for this study, provided they may receive full dose radiation to the current SCCHN cancer
+Patients must have histologically squamous cell carcinoma of the head and neck and be planned for definitive radiation and chemotherapy
+Patients may have received induction therapy prior to definitive therapy for the current head and neck cancer
+Patients may have a history of prior malignancy, but must be able to tolerate full dose radiation and chemotherapy for the current head and neck cancer, as determined by the treating oncologist
+Previous head and neck radiation therapy involving the glottic larynx
+Prior therapy to the head and neck, with the intent to treat, the current diagnosis of head & neck cancer
+Patient with newly diagnosed or recurrent, histologic diagnosis of lung cancer or head & neck cancer (categories: oral cavity, pharynx and larynx only)
+Clinical diagnosis of squamous cell cancer of the head and neck (non-nasopharynx primary tumors: oral cavity, oropharynx, hypopharynx and larynx) or skin
+Subjects with prior head and neck radiation therapy
+Histologically or cytologically confirmed squamous cell carcinoma of the head and neck
+Histologically/cytologically confirmed diagnosis of squamous cell carcinoma of head and neck origin not amenable to curative intent therapy; both human papillomavirus (HPV)(+) and HPV(-) tumors are eligible; tumors (squamous histology) of unknown primary that are clearly of squamous histology and likely related to the head and neck area are eligible
+Prior chemotherapy or radiosensitizers for cancer of the head and neck (except for T1 glottic cancer) that would result in an overlap of radiation fields.
+Prior radiation therapy to the head or neck, which would result in overlap of radiation therapy fields
+Patient must have histologically or cytologically confirmed diagnosis of incurable metastatic or recurrent head and neck squamous cell carcinoma
+No previous surgery, radiation therapy or chemotherapy for squamous cell carcinoma of the head and neck (SSCHN) (other than biopsy or tonsillectomy) is allowed at time of study entry
+Histologically confirmed, previously untreated invasive head and neck squamous cell carcinoma OR histologically confirmed not yet treated recurrent head and neck squamous cell carcinoma (must be at least 3 months after diagnosis and completion of treatment for primary disease or last recurrence); patients may have local stage I or II, or locoregionally advanced HNSCC stage III or IV of the oral cavity, oropharynx, larynx, hypopharynx, or unknown primary, but no metastatic disease; intent to treat with primary radiotherapy +/- chemotherapy
+Patient must not have outside nodal tissue from previous neck biopsy/neck dissections in which ECS cannot be confirmed or denied
+Pathologically confirmed diagnosis of cancer, including, but not limited to non-small cell lung cancer, breast, prostate, renal cell, melanoma, gastrointestinal, sarcoma, thyroid, head and neck primary, and carcinoma of unknown primary
+Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
+Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation therapy for localized cancer of the breast, head and neck, or skin is permitted provided that it was completed more than 3 years prior to registration, and the patient remains free of recurrent or metastatic disease
+Reirradiation targets located within the head, neck, or brain are excluded from this study
+Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of cervical cancer within the last three years are excluded            \r\n* Prior radiation for localized cancer of the breast, head and neck, or skin is permitted provided that it was completed more than three years prior to registration and the patient remains free of recurrent or metastatic disease
+Patients who had prior head and neck radiation therapy
+Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease.
+Any N stage but resectable; lymph nodes in both sides of the neck are at risk of metastatic disease, according to clinical judgment, and require irradiation; pre-treatment surgery in the neck in the forms of incisional/excisional biopsy or a multilevel neck dissection is allowed only if there is gross tumor left at the primary site
+Previous irradiation for head and neck tumor; concurrent chemotherapy other than the treatment per protocol; previous chemotherapy =< 3 months from start of radiation therapy (RT)
+Prior malignancies at sites other than the head and neck are allowable if there has been greater than or equal to a 3 year disease free interval; basal cell carcinoma of the skin and in-situ cervix dysplasias are allowable within this 3 year interval if completely resected
+Histologically confirmed metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) of the oral cavity, oropharynx, hypopharynx or larynx; metastatic or recurrent lesions of the nasopharynx and sinus are excluded
+Patients must have cytologically or histologically proven recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) from the primary tumor or lymph nodes of the oral cavity, larynx, oropharynx, or hypopharynx.
+No prior systemic chemotherapy for patients who present with metastatic disease. For patients with recurrent head and neck squamous cell carcinoma, prior chemotherapy is allowed if it was given as part of their definitive therapy. If patients have received prior combined modality therapy, they must be off therapy for at least 6 months.
+Histologically confirmed squamous cell carcinoma of the head and neck (SCCHN), from any of the following primary sites only: oral cavity, oropharynx, hypopharynx, and larynx.
+Prior radiation to the head and neck
+Radiation therapy: patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
+Confirmed squamous cell carcinoma of the head and neck (oropharynx, oral cavity, hypopharynx, or larynx) or skin
+Patients with prior history of head and neck radiotherapy (> 40 Gy) with significant areas of anticipated overlap
+Histological or cytological diagnosis of squamous cell carcinoma (SCC) of head and neck with American Joint Committee on Cancer (AJCC) Stage III, IVA or IVB and not amenable to surgical resection or locoregional radiation therapy with curative intent.
+Patients may not have received previous therapy for their head and neck SCC, including chemotherapy, radiation therapy, or surgery beyond biopsy
+confirmed SCC of the head and neck, lung, or esophagus
+Metastatic colorectal cancer or head and neck squamous cell carcinoma
+Histologically or cytologically confirmed loco-regionally advanced head and neck squamous cell carcinoma (HNSCC), stage III to IVb
+Histologic or cytologic confirmation of head and neck malignancy without clinical or radiographic evidence of metastatic disease
+Locally advanced head and neck (HN) squamous cell carcinoma (SCC), stages III, IV, and bulky (> 27 cm^3 volume) stage II, excluding larynx and nasopharynx, of no more than 150 cm^3 volume base on CT scan
+Histologically confirmed metastatic head and neck squamous cell carcinoma (HNSCC), including nasopharynx World Health Organization (WHO) type I-III histologies; patients can have simultaneous loco-regional disease; central biopsy review at Memorial Sloan-Kettering Cancer Center (MSKCC) is not required
+Histologically proven squamous cell carcinoma of the head and neck with measurable disease that is either recurrent after attempted cure with surgery and/or radiation therapy or newly diagnosed disease with distant metastases or incurable at diagnosis
+No prior chemotherapy for metastatic squamous cell carcinoma of the head and neck; subjects who have received chemotherapy as part of a multi-modality curative approach for head and neck cancer will be eligible as long as they have not received either docetaxel or capecitabine (or fluorouracil [5-FU]) as part of that regimen
+Prior chemotherapy for metastatic squamous cell carcinoma of the head and neck; subjects who have received chemotherapy as part of a multi-modality curative approach for head and neck cancer will be eligible as long as they have not received either docetaxel or capecitabine (or 5-FU) as part of that regimen
+Squamous cell carcinoma of the Head and Neck
+Diagnosis of BCC with at least 6 nodular lesions that measure 0.5 cm to 5 cm in diameter, located on the head and neck, trunk or extremities
+Histologically or cytologically confirmed recurrent or metastatic squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx) that is incurable by local therapy.
+Subjects with a diagnosis of head and neck cancer biopsy proven, and who have a scheduled appointment for definitive resection of the tumor at Thomas Jefferson University Hospital (TJUH) are eligible to participate
+Patients scheduled for definitive head and neck squamous cell carcinoma (HNSCC) cancer surgical resection less than 9 days from enrollment or greater than five weeks from enrollment
+Head and neck squamous cell carcinoma
+Patients with prior primary treatment for head and neck cancer (e.g. chemoradiation or radiation alone).
+Subjects with advanced/metastatic Squamous cell carcinoma of the head and neck (SCCHN) who are without options for curative treatment
+Prior radiation to the head and neck.
+Participants with unknown primary SCCHN presumed to be of head and neck mucosal origin are eligible if they meet all other entry criteria
+Head and neck squamous cell carcinoma (HNSCC) Cohort: Participants with histologically confirmed inoperable, locally advanced or metastatic, recurrent, or persistent HNSCC (oral cavity, oropharynx, hypopharnyx, or larynx) not amenable to curative therapy not previously treated with anti-PD-L1/PD-1 and/or anti-CTLA-4 (investigational or approved)
+A minimum of 4 Squamous Cell Carcinomas of the Head and Neck (Sq-HNC)
+Histologically confirmed Stage III or IV recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
+Part B- Diagnosed with adenocarcinoma of the colon or rectum, head and neck squamous cell carcinoma, uveal melanoma with liver with metastasis, or cholangiocarcinoma
+Part C - Diagnosed with head and neck squamous cell carcinoma and have received at least one prior platinum-based systemic therapy
+Ability to swallow capsules, with the exception of head and neck squamous cell carcinoma participants who may have study drug crushed and administered through a feeding tube
+Histologically documented diagnosis of locally advanced or metastatic squamous cell carcinoma (SCC) of the head and neck no longer amenable to curative surgical resection or radiation therapy
+Have a history of bladder neck contracture,
+Prior cranial radiotherapy or radiotherapy to the head and neck where potential field overlaps would exist
+Diagnosis of any of the following cancers: stage 1-4b (includes 4a) oropharyngeal, hypopharyngeal, nasopharyngeal, salivary gland or oral cavity; stage 3-4b (includes 4a) laryngeal; any unknown primary head and neck cancer with cervical metastasis that will be addressed with treatment to bilateral necks and mucosa; any thyroid cancer that will be addressed with treatment to the bilateral necks; or other head and neck cancers medically approved by one of our Radiation Oncology collaborating medical doctors (MDs)
+Received previous radiation treatment for head and neck cancer
+Patient is initiating radiation therapy (XRT) for head and neck cancer (HNC)
+Has cancer outside of the oropharynx, larynx, and hypopharynx or oral cavity, such as nasopharyngeal, sinus, other para-nasal, or other unknown primary head and neck cancer
+Has had prior systemic therapy, targeted therapy, radiotherapy treatment or radical surgery for head and neck cancer under study
+Patients undergoing free flaps for reconstruction of head and neck surgical defects at University of California (UC) Davis Medical Center (UCDMC), including but not limited to, head and neck cancer defects, osteoradionecrosis (ORN), and trauma
+Histologically confirmed locally advanced cancer of mucosa of the head and neck.\r\n* Eligible subsites will include nasal cavity, paranasal sinuses, nasopharynx, oropharynx, oral cavity, major salivary glands, oropharynx, larynx, hypopharynx, cervical esophagus, or unknown primary site with lymph node metastases.\r\n* Clinical or pathologic stage III-IV
+Patients must be diagnosed with cancer of the head and neck and must be surgical candidates
+History of head injury
+Completed treatment for a head or neck cancer at this institution within 4 months of consent OR will complete treatment for a head and neck cancer at this institution within 3 weeks of consent
+Patients receiving brain RT for intracranial disease (including recurrent head and neck tumors with base of skull or intracranial extension) or for prophylactic cranial irradiation, over 2-6 weeks period of time
+Patient requires a neck brace for medical reasons
+Patient has no history of prior neck surgery or external radiation to neck for malignant conditions
+Full range of motion in the neck
+Limited neck movement
+Histologically proven cancer of the head and neck cancer
+Patients with head and neck cancer who plan to undergo radiation therapy to the head and neck region
+Patients with prior radiation therapy to the head and neck region or prior chemotherapy for head and neck cancer (induction chemotherapy not excluded)
+Patients being treated for oropharyngeal cancer with undergoing concurrent chemotherapy and radiation therapy (photons) for a histological diagnosis of squamous cell carcinoma to the head and neck at the University of Pennsylvania
+Subjects diagnosed with head and neck tumors (any histology) receiving ongoing chemoradiation or radiation therapy
+Patients actively receiving radiation to the head, neck, or gastrointestinal tract
+Cervical or head/neck cancer diagnosis in the past 5 years
+Patients with a definitive, curative treatment plan consisting of chemoradiation for head & neck cancer\r\n* Surgery, if required, must be limited to: diagnostic biopsy
+No more than 6 weeks after completion of initial lymphedema therapy for head and neck lymphedema
+Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
+Patients who are eligible for chemoradiation therapy of the head and neck
+Have a clinical stage II-IV head and neck carcinoma
+Have a pathologic diagnosis of squamous cell carcinoma of the head and neck region
+Patients who have previously been treated with surgery or radiation for head and neck cancer and/or are being treated for recurrent head and neck cancer
+Patients with American Joint Committee on Cancer (AJCC) stage II-IV head and neck squamous cell carcinoma who are beginning first-line non-surgical treatment with concurrent chemoradiotherapy (CCRT) and who are capable of understanding and adhering to the protocol requirements
+Patients receiving prior external beam irradiation to the head or neck, including any form of stereotactic irradiation
+Pathologically-confirmed diagnosis of squamous cell carcinoma of the head and neck, defined as SCC of the oral cavity or oropharynx that will be treated with cisplatin plus concurrent IMRT Note: Patients with unknown primary tumors whose treatment plan matches the requirements specified in Inclusion Criteria #2 and #3 below are eligible for the trial.
+Subjects with a diagnosis of head and neck cancer biopsy proven, and who are candidates for radiation therapy
+Must have received and completed radiotherapy with or without chemotherapy for head and neck cancer; time from completion of radiotherapy to registration must be at least 3 months and up to a maximum of 1 year
+Diagnosed with head and neck cancer, which will be primarily nasopharyngeal, and scheduled to undergo intensity-modulated radiation therapy (IMRT) or proton with or without concurrent chemotherapy at MD Anderson or Fudan University
+History of xerostomia prior to head and neck radiation therapy or history of Sjögren's disease or another underlying systemic illness known to cause xerostomia
+Prior head and neck radiation treatment
+Prior history of radiation therapy to the head and neck
+Prior history of head and neck cancer
+Previous receipt of head and neck irradiation
+Patients with head and neck cancer who are undergoing either flap or nonflap surgery (limited to parotidectomy, hard palate maxillectomy and glossectomy, mandibulectomy, and any procedure with neck dissection) at MD Anderson Cancer Center
+> 3 months post-treatment of head and neck cancer (HNC)
+Diagnosed with head and neck cancer, which will be primarily oropharyngeal, and scheduled to undergo intensity modulated radiation therapy (IMRT) with or without concurrent chemotherapy at M. D. Anderson
+History of xerostomia prior to head and neck radiation therapy or history of Sjögren's disease or another underlying systemic illness known to cause xerostomia
+Prior head and neck radiation treatment
+Has had prior radiation to the head and neck
+Subjects undergoing definitive mucosal head and neck tumor resection including oral cavity, oropharynx, larynx, and hypopharynx
+Patients who are scheduled to undergo radiation or chemoradiation treatment for head/neck cancer
+Knowledgeable in head and neck lymphedema management
+Completion of lymphedema therapy for lymphedema of the head and neck
+Patients with underlying diagnosis of metastatic colorectal cancer or head and neck squamous cell carcinoma including newly diagnosed patients
+Previous or concurrent radiation therapy to head, neck, and chest (i.e. application sites only)
+Pathologically-confirmed diagnosis of squamous cell carcinoma of the head and neck (SCCHN), defined as SCC of the oral cavity or oropharynx, that will be treated with standard cisplatin and Intensity-Modulated Radiation Therapy (IMRT)
+Patients who will undergo complex head and neck surgery in addition to the TORS procedure requiring reconstruction with a free flap
+Patients who have had any previous head and neck surgery that has affected swallowing, voice or speech or who have had previous radiation to the head or neck
+Previous or concurrent radiation treatment to the head and neck region
+Prior head and neck RT
+Personal history of lung cancer or head and neck cancer
+Patients must be receiving cisplatin therapy for a non-head and neck malignancy in total doses >= 100 mg/m^2
+Patients must be scheduled to receive RT or CRT as definitive treatment or adjuvant RT or CRT treatment post-surgery per surgeon or Head and Neck Cancer (HNC) Tumor Board decision
+History of prior head and neck squamous cell carcinoma (HNSCC) unless curatively treated for >= 1 year
+Head and neck squamous cell carcinoma:
+Prior radiation to the head and neck
+Urethral stricture/bladder neck contracture
+Patients with previous head and neck (H&N) radiation
+Patients with oral cavity squamous cell cancer requiring neck dissection
+Must have a diagnosis of head/neck cancer
+Must have anatomically intact parotid glands and at least one submandibular gland; a focused (head/neck) history and exam conducted by a physician or dentist within the past year is required
+History of xerostomia, Sjogren’s disease or other illness known to affect salivation prior to head/neck radiation
+Histologically or cytologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN)
+Histologically proven squamous cell carcinoma of the head and neck (SCCHN) from one of the following primary sites: oral cavity, oropharynx, hypopharynx, and larynx
+Personal history of lung cancer or head and neck cancer
+Subject has received prior radiation to the head and neck region (+/- chemotherapy).
+Subjects with head and neck cancer involving the oropharynx or oral cavity, who are expected to undergo high dose radiation therapy (i.e., ? 60 Gy) that typically results in oral mucositis, with or without concurrent chemotherapy or biologic targeted therapy.
+diagnosis of head and neck cancer
+Evidence of current disease with lung cancer or head and neck cancer
+Patients may have a prior history of lung cancer or head and neck cancer treated with curative intent, provided that there has been no evidence of disease (NED) for > 1 year; the qualifying autofluorescence (AF) bronchoscopy must be negative for malignancy
+Within two weeks of starting or one week from having started, radiation therapy +/- chemotherapy for head and neck cancer
+Diagnosed with melanoma or lymphoma cancer of the head and neck
+Patients with biopsy-proven oral squamous cell carcinoma (SCC) who are scheduled to undergo surgery in the Memorial Sloan Kettering (MSK) Head and Neck Service
+Group 1 patients: Presence of a suspicious metastatic lesion or suspicious for recurrent disease in the head and neck region
+Group 2 patients:\r\n* Biopsy proven recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC)\r\n* Patients planning to undergo investigational therapy
+Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
+Confirmed or suspected head and neck tumor (benign or malignant)
+Patients undergoing staging endoscopy for head and neck squamous cell carcinoma (HNSCCa)
+Adult patients seen in the Head and Neck Tumor Clinic who will require laryngoscopy in the operating room for diagnosis and staging of known or suspected tumors of the upper aerodigestive tract (UADT)
+History of prior surgery or radiation to the head, neck, upper limb, or trunk
+Patients with histologically proven diagnosis of head and neck cancer or patients with tumors strongly suspicious for head and neck cancer due to clinical features or FNA (fine needle aspiration) cytology assessment
+Patients with a history of head and neck cancer or oral premalignant disease but without any clinical evidence of disease
+Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck
+Patients diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection, including a (modified) neck dissection
+Biopsy proven, squamous cell carcinoma of the head and neck
+Participant with histologic confirmation of newly diagnosed squamous cell carcinoma (SCC) of the head and neck
+Participant with unilateral or bilateral neck dissection planned for care; an N0 neck must be planned to be dissected for the patient to be eligible; the N0 neck can be either ipsilateral to the head and neck tumor or the contralateral N0 neck if a bilateral neck dissection is planned
+Participant with at least one neck that is clinically N0 as defined by clinical exam (physical exam with CT and/or MRI as the gold standard of the N0 neck); stages T2, T3, or T4. N0–N3, excluding N2c for bilateral disease based on criteria from the American Joint Commission on Cancer
+Patient with tumors in the head and neck that are not SCC
+Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck
+Patients diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection; patients with recurrent disease or a new primary will be allowed
+Histologically or cytologically confirmed head and neck squamous cell carcinoma.
+Diagnosed with advanced NSCLC, breast cancer, GBM or other cancers (such as head and neck, colorectal, pancreatic, renal cancers); patients will undergo anti-angiogenesis treatment or treatment with other drugs that may alter angiogenesis
+Histologically confirmed diagnosis of head and neck carcinoma (excluding nasopharynx, paranasal sinus, salivary, and thyroid malignancies); any unknown primary squamous cell carcinoma of head and neck with gross nodes is allowed
+Any prior radiotherapy to the head and neck region
+Patients must have had pathologic lymph nodes in the neck, axillary or inguinal area (do not need to be biopsy proven) from either leukemias, lymphomas; head and neck cancers (e.g. tonsillar, nasopharynx, tongue carcinoma), breast cancer or melanoma; or thyroid cancer for thyroid ablation therapy; any other more infrequent cancer with nodal metastasis in the neck, axilla, and inguinal regions is eligible as well as the primary goal is to image pathological (i.e. hypermetabolic) lymph nodes
+Patient must not have a history of radiation to the neck
+Patients with indications for initial total thyroidectomy (TT) including preexisting hypothyroidism or history of head and neck radiation when < 18 years old will be excluded.
+Patients with a variety of malignancies (i.e., melanoma, sarcoma, colon, head and neck,\r\nrenal, breast, lung, ovary, liver)
+Patients with a diagnosis of head and neck cancer biopsy proven, and who have a scheduled appointment for definitive resection of the tumor at Thomas Jefferson University Hospital (TJUH) are eligible to participate
+Patients with history of prior radiation therapy or radioactive iodine to the head and neck
+Patients undergoing bilateral neck dissection
+Patients undergoing neck skin defect reconstruction
+Pre-intervention: 200 patient records between January 1, 2016 and December 31, 2016 are subject to review; the first 50 records with a diagnoses of each cancer type: head and neck, lung, prostate, or breast will be utilized for the review
+Diagnosis of any of the following cancers: stage 1-4b oropharyngeal, hypopharyngeal, nasopharyngeal, salivary gland or oral cavity; stage 3-4b laryngeal; any unknown primary head and neck cancer with cervical metastasis that will be addressed with treatment to bilateral necks and mucosa; or other head and neck cancers medically approved by one of our Radiation Oncology collaborating medical doctors (MDs) (Arms 2 and 3)
+Diagnosed Head and Neck Cancer patients with planned Radiation therapy
+Planned RT to the head/neck
+Patients must have histologically confirmed head-and-neck, lung, or prostate tumors
+Radiation oncology patients undergoing 6-7 weeks of definitive radiation therapy for stage III-IV head and neck squamous cell carcinoma (HNSCC)
+Locally advanced or metastatic head and neck cancer.
+Subjects have head and neck cancer as defined in history and physical